MS News That Caught My Eye Last Week: Pediatric MS, Rituximab, AHSCT, Zeposia

MS News That Caught My Eye Last Week: Pediatric MS, Rituximab, AHSCT, Zeposia

284799

MS News That Caught My Eye Last Week: Pediatric MS, Rituximab, AHSCT, Zeposia

Tecfidera Safe and Effective Over Long Term in Children With RRMS, Trial Shows In my view, too little attention has been paid to treating children and teens with MS between the ages of 10 and 18. Though things seem to be improving, only one disease-modifying therapy, Novartis’ Gilenya (fingolimod), is approved in the U.S. to treat pediatric MS. So, I’m always on the alert for information about other DMTs that are being studied for possible…

You must be logged in to read/download the full post.